



Suite 2380 – 1055 West Hastings Street, Vancouver, BC V6E 2E9

Not for distribution to U.S. Newswire Services or for dissemination in the United States.

May 14, 2024

Trading Symbol: TCC

TRENCHANT ANNOUNCES CHANGE OF NAME AND TRADING SYMBOL

VANCOUVER, BC – Trenchant Capital Corp. (CSE: TCC) (“Trenchant” or the “Company”) is pleased to announce that the Company intends to change its name to “Trenchant Technologies Capital Corp.” from “Trenchant Capital Corp.” and begin trading on the Canadian Securities Exchange (“CSE”) under the new name at the market open on May 17, 2024. Concurrently with the name change, the Company will also change its stock symbol to “AITT” on the CSE. No action is required to be taken by shareholders with respect to the name change. Outstanding share certificates are not affected by the name change and do not need to be exchanged. The Company’s ISIN and CUSIP numbers for the common shares will change to CA8949431099 and 894943109, respectively.

The Company’s decision to change its name better reflects its focus on seeking investments in companies that are leveraging novel technologies (Artificial Intelligence (“AI”) and Quantum Computing, for example) in traditional business models to accelerate growth and provide competitive advantage. The Company’s initial investment is a 20% ownership in GNQ Insilico Inc. (“GNQ”) with an option to acquire up to a 50% ownership interest. GNQ was formed by My Next Health Inc. (“MNH”), a Delaware incorporated healthcare company with a vision to improve the global healthcare sector by deploying a genomics-based AI and quantum platform for clinical trials and point of care solutions. GNQ’s platform uses proprietary insights on how systems of genes interact with each other as well as with epigenetic factors to drive key metabolic pathways. These insights are based on more than 15,000 case studies conducted over a decade and are now being scaled and commercialized through a platform that will leverage key exponential technologies to revolutionize personalized healthcare. It is GNQ’s belief that the successful deployment of its genomics-driven generative AI in silico clinical trials platform powered by quantum computing has the potential to provide the following benefits to drug development:

Rapid Drug Development: In silico clinical trials enable GNQ to expedite the drug development process by simulating and predicting drug responses, significantly reducing the time required for clinical trials and the overall cost of the trials.

Improved Safety and Efficacy: In silico clinical trials enhance GNQ’s understanding of drug mechanisms, allowing for the prediction of adverse effects and optimization of drug dosages, thereby increasing safety and efficacy.

Personalized Medicine: GNQ's generative AI platform simulates the effects of drugs across diverse profiles of human digital twins (digital replicas of real people), enabling the development of targeted therapies and facilitating personalized medicine across disparate and diverse populations.

Equitable Representation: GNQ's drug simulation process is inherently designed to include genetic, epigenetic and lifestyle variances based on ethnic and minority populations, thereby ensuring equitable representation of underserved minorities in the drug development process.

MNH owns exclusive and perpetual global rights to the use of certain technology that relates to functional genomics as well as the supporting clinical data, programs, methods, and interpretation know-how and analytics for use in a number of commercial applications.

For more information on GNQ, see its website at <https://gnqin.com/>.

The Company further announces that it engaged the services of Aktiencheck.de AG ("**Aktiencheck**") to provide investor relations services and assistance with a listing in Frankfurt in compliance with the policies and guidelines of the CSE and other applicable legislation. The agreement between the Company and Aktiencheck is dated May 14, 2024. The market awareness services to be conducted by Aktiencheck will include marketing and communicating with institutional and professional investors, private equity funds, and retail brokers, investor presentations and other related investor relation services including the writing and dissemination to the European investment community of research reports on the Company.

Under the terms of the agreement, Aktiencheck will receive a one-time fee of €57,000 for a twelve (12) month term, unless otherwise terminated earlier in accordance with its terms. No stock options or other compensation securities were granted in connection with the engagement. Aktiencheck's contact information is as follows: Bahnhofstraße 6, 56470, Bad Marienberg, Germany, attention: Stefan Lindam, Chief Executive Officer, email: stefan.lindam@aktiencheck.de, telephone: +49 (2661) 989-0020. Neither Aktiencheck or Mr. Lindam, the Chief Executive Officer of Aktiencheck, own any securities of the Company. Aktiencheck and its clients may acquire additional interests in the securities of the Company in the future.

**ON BEHALF OF THE BOARD
TRENCHANT CAPITAL CORP.**

Per: "Eric Boehnke"
Eric Boehnke, CEO

For further information, please contact:
Trenchant Capital Corp.
Eric Boehnke, CEO
Phone: (604) 307-4274

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements

regarding: the Offering and its terms, including the intended use of proceeds of the Offering and additional tranches of the Offering may not close on the terms announced or at all; and other matters regarding the business plans of the Company. The forward-looking statements reflect management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including: that additional tranches of the Offering may not close at all or on the terms announced; that the Company may use the proceeds of the Offering for purposes other than those disclosed in this news release; adverse market conditions; and other factors beyond the control of the Company. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.

The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.